Overview

Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, early bactericidal activity (EBA) and pharmacokinetics of TBA-7371 in adult participants with rifampicin-sensitive tuberculosis and select dose regimen(s) for future studies.
Phase:
Phase 2
Details
Lead Sponsor:
Bill & Melinda Gates Medical Research Institute
Treatments:
Rifampin